RecruitingPhase 1
Safety, PK and PD of FLQ-101 in Premature Neonates
FELIQS INC. · NCT07093255
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 0 mo–0 mo · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 1
- Target enrollment
- 18
- US sites recruiting
- 1
- Study start
- April 3, 2026
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
Being studied: FLQ-101
Conditions: Retinopathy of Prematurity (ROP)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Written consent is obtained from parent(s) or legal guardian.
- Neonates born at 25 weeks +0 days and 27 weeks +6 days of gestation.
Exclusion Criteria
- Neonates with congenital malformation of the eye or any other ocular condition that may prevent or relevantly affect any of the assessments or procedures.
- Neonates with serious congenital anomalies, severe congenital infection, and chromosomal abnormalities.
- Neonates who are seriously ill and not expected to survive.
- Neonates with heart disease, including cardiomyopathy, serious arrhythmias, and congenital heart disease. (Neonates with patent foramen ovale may be included in the study if clinically stable).
- Neonates that are small for gestational age defined as having a weight \<10th percentile at birth based on the Fenton growth charts for gestational age and sex.
- Neonates with history of or ongoing intraventricular hemorrhage (IVH) grades 2, 3 or 4. Neonates with IVH grade 1 may be included in the study at the discretion of the PI.
- Neonates with any other medical conditions or clinically significant comorbidities or circumstances that in the opinion of the investigator may have a relevant impact on study participation or any of the study assessments or procedures.
- Infants scheduled to participate in other interventional clinical trials while participating in the study and until reaching end of study.
Recruiting US locations
St. David's Medical Center
Austin, TX 78705
Site contact: Clininical Research Cordinator · 512-544-8070
Study contacts (from the official record)
- Clinical Trial Office · +81-942-707-330 · clinicaltrial@feliqs.com
Similar studies in Texas
All phase 1 studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75